200 related articles for article (PubMed ID: 36976507)
1. Structure-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation of EGFR for the Clinical Treatment of Glioblastoma.
Bhrdwaj A; Abdalla M; Pande A; Madhavi M; Chopra I; Soni L; Vijayakumar N; Panwar U; Khan MA; Prajapati L; Gujrati D; Belapurkar P; Albogami S; Hussain T; Selvaraj C; Nayarisseri A; Singh SK
Appl Biochem Biotechnol; 2023 Aug; 195(8):5094-5119. PubMed ID: 36976507
[TBL] [Abstract][Full Text] [Related]
2. Identification of Potent VEGF Inhibitors for the Clinical Treatment of Glioblastoma, A Virtual Screening Approach.
Yadav M; Khandelwal R; Mudgal U; Srinitha S; Khandekar N; Nayarisseri A; Vuree S; Singh SK
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2681-2692. PubMed ID: 31554364
[TBL] [Abstract][Full Text] [Related]
3. Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma.
Lu H; Zhang B; Xie Y; Zhao W; Han W; Zhou L; Wang Z
Invest New Drugs; 2023 Aug; 41(4):564-578. PubMed ID: 37322389
[TBL] [Abstract][Full Text] [Related]
4. A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer.
Sharda S; Khandelwal R; Adhikary R; Sharma D; Majhi M; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(13):1129-1144. PubMed ID: 31109278
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation of VEGF inhibitors for the clinical treatment of Ovarian Cancer.
Mukherjee S; Abdalla M; Yadav M; Madhavi M; Bhrdwaj A; Khandelwal R; Prajapati L; Panicker A; Chaudhary A; Albrakati A; Hussain T; Nayarisseri A; Singh SK
J Mol Model; 2022 Mar; 28(4):100. PubMed ID: 35325303
[TBL] [Abstract][Full Text] [Related]
6. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
7. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
8. An In Silico Investigation of Potential EGFR Inhibitors for the Clinical Treatment of Colorectal Cancer.
Majhi M; Ali MA; Limaye A; Sinha K; Bairagi P; Chouksey M; Shukla R; Kanwar N; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2018; 18(27):2355-2366. PubMed ID: 30499396
[TBL] [Abstract][Full Text] [Related]
9. Structure-based Virtual Screening for the Identification of High-affinity Small Molecule Towards STAT3 for the Clinical Treatment of Osteosarcoma.
Khandelwal R; Chauhan APS; Bilawat S; Gandhe A; Hussain T; Hood EA; Nayarisseri A; Singh SK
Curr Top Med Chem; 2018; 18(29):2511-2526. PubMed ID: 30430945
[TBL] [Abstract][Full Text] [Related]
10. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
[TBL] [Abstract][Full Text] [Related]
12. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
Roos A; Dhruv HD; Peng S; Inge LJ; Tuncali S; Pineda M; Millard N; Mayo Z; Eschbacher JM; Loftus JC; Winkles JA; Tran NL
Mol Cancer Res; 2018 Jul; 16(7):1185-1195. PubMed ID: 29724813
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
14. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.
Zhu Y; Shah K
Cancer Biol Ther; 2014 Jun; 15(6):815-22. PubMed ID: 24658109
[TBL] [Abstract][Full Text] [Related]
15. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
16. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
Eskilsson E; Røsland GV; Solecki G; Wang Q; Harter PN; Graziani G; Verhaak RGW; Winkler F; Bjerkvig R; Miletic H
Neuro Oncol; 2018 May; 20(6):743-752. PubMed ID: 29040782
[TBL] [Abstract][Full Text] [Related]
17. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
[TBL] [Abstract][Full Text] [Related]
18. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches.
Jethwa M; Gangopadhyay A; Saha A
J Biomol Struct Dyn; 2023 Mar; 41(5):1681-1689. PubMed ID: 35014597
[TBL] [Abstract][Full Text] [Related]
19. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
[TBL] [Abstract][Full Text] [Related]
20. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
